% ============================================================================
% CONSTRAINT STORY: cellular_manipulation_standards
% ============================================================================
% Version: 1.0 (Deferential Realism Core + Directionality + Boltzmann + Network)
% Logic: 6.0 (Indexed Tuple P,T,E,S + Sigmoid f(d) + Coupling + Purity + Network)
% Generated: 2026-02-26
% Status: [ACTIVE]
% ============================================================================

:- module(constraint_cellular_manipulation_standards, []).

:- use_module(constraint_indexing).
:- use_module(domain_priors).
:- use_module(narrative_ontology).

% --- Constraint Identity Rule (DP-001: ε-Invariance) ---
% Each constraint story must have a single, stable base extractiveness (ε).
% If changing the observable used to evaluate this constraint would change ε,
% you are looking at two distinct constraints. Write separate .pl files for
% each, link them with affects_constraint/2, and document the relationship
% in both files' narrative context sections.
%
% The context tuple is CLOSED at arity 4: (P, T, E, S).
% Do not add measurement_basis, beneficiary/victim, or any other arguments.
% Linter Rule 23 enforces context/4.
%
% See: epsilon_invariance_principle.md

% --- Namespace Hooks (Required for loading) ---
:- multifile
    domain_priors:base_extractiveness/2,
    domain_priors:suppression_score/2,
    domain_priors:theater_ratio/2,
    domain_priors:requires_active_enforcement/1,
    narrative_ontology:has_sunset_clause/1,
    narrative_ontology:interval/3,
    narrative_ontology:measurement/5,
    narrative_ontology:constraint_metric/3,
    narrative_ontology:constraint_beneficiary/2,
    narrative_ontology:constraint_victim/2,
    narrative_ontology:constraint_claim/2,
    narrative_ontology:affects_constraint/2,
    narrative_ontology:coordination_type/2,
    narrative_ontology:boltzmann_floor_override/2,
    constraint_indexing:constraint_classification/3,
    constraint_indexing:directionality_override/3,
    narrative_ontology:omega_variable/3,
    narrative_ontology:human_readable/2,
    narrative_ontology:topic_domain/2.

/* ==========================================================================
   1. NARRATIVE CONTEXT
   ========================================================================== */

/**
 * CONSTRAINT IDENTIFICATION
 *   constraint_id: cellular_manipulation_standards
 *   human_readable: Cellular Manipulation Standards (CRISPR/Gene Editing Governance)
 *   domain: biotechnology/life_sciences/governance
 *
 * SUMMARY:
 *   Cellular manipulation standards — the regulatory frameworks and technical
 *   specifications governing CRISPR gene editing and related technologies —
 *   exhibit a classic tangled rope structure: genuine coordination benefit
 *   (standardized protocols reduce R&D time, enable quality assurance,
 *   facilitate international collaboration) layered with significant
 *   asymmetric extraction (barriers to entry concentrate capability in
 *   wealthy institutions, developing-world researchers are locked into
 *   dependency on proprietary tools and centralized approval pathways). The
 *   constraint has evolved from primarily coordination (early standardization
 *   phase, 2012–2016) toward mixed coordination-extraction (current phase,
 *   2020–2026) as the technology matured and became economically valuable.
 *   The extractiveness trajectory (0.28 → 0.52 over 10 years) reflects
 *   rent-seeking layered onto genuine standardization. The theater ratio
 *   progression (0.35 → 0.58) indicates that institutional review mechanisms
 *   (biosafety committees, regulatory approval gates) have become
 *   increasingly performative relative to actual safety risk assessment — the
 *   real risk management happens in upstream designer verification and
 *   downstream clinical trials, not in the review process itself.
 *
 * KEY AGENTS:
 *   - Established Biotech Corporations: Primary beneficiary (institutional/arbitrage) — capture value from standardization, benefit from economies of scale, have low exit costs
 *   - Independent Researchers (Global South): Primary victim (powerless/trapped) — face cumulative barriers (equipment, reagent access, regulatory compliance, institutional affiliation requirements); cannot exit without abandoning research
 *   - Emerging Market Biotech Firms: Secondary victim (moderate/constrained) — can theoretically exit by relocating or pivoting technology platform, but face significant costs; also genuinely benefit from standardized protocols
 *   - National Regulatory Authorities: Institutional enforcer (institutional/constrained) — maintain standards compliance while partly captured by international norms and corporate influence in standards bodies
 *   - Open Science Coalition: Organized agents (organized/mobile) — building alternative infrastructure (open-source tools, patent pools, community-led standards) with clear sunset trajectory
 *   - Institutional Biosafety System: Degraded ritual (institutional/arbitrage) — performs safety theater through committee checklist processes that no longer reflect actual risk assessment
 *   - Analytical Observer: Universal perspective (analytical/analytical) — risks naturalizing contingent governance as inherent biosafety requirement
 */

/* ==========================================================================
   2. BASE PROPERTIES (DOMAIN PRIORS)
   ========================================================================== */

% --- Numerical metrics ---
domain_priors:base_extractiveness(cellular_manipulation_standards, 0.52).
domain_priors:suppression_score(cellular_manipulation_standards, 0.65).
domain_priors:theater_ratio(cellular_manipulation_standards, 0.58).

% --- Constraint metric facts (engine primary keys, must mirror domain_priors) ---
narrative_ontology:constraint_metric(cellular_manipulation_standards, extractiveness, 0.52).
narrative_ontology:constraint_metric(cellular_manipulation_standards, suppression_requirement, 0.65).
narrative_ontology:constraint_metric(cellular_manipulation_standards, theater_ratio, 0.58).

% --- Constraint claim ---
narrative_ontology:constraint_claim(cellular_manipulation_standards, tangled_rope).
narrative_ontology:human_readable(cellular_manipulation_standards, "Cellular Manipulation Standards (CRISPR/Gene Editing Governance)").
narrative_ontology:topic_domain(cellular_manipulation_standards, "biotechnology/life_sciences/governance").

domain_priors:requires_active_enforcement(cellular_manipulation_standards).

% --- Structural relationships ---
narrative_ontology:constraint_beneficiary(cellular_manipulation_standards, institutional_biotech_firms).
narrative_ontology:constraint_beneficiary(cellular_manipulation_standards, research_institutions_with_resources).
narrative_ontology:constraint_beneficiary(cellular_manipulation_standards, regulatory_bodies).
narrative_ontology:constraint_victim(cellular_manipulation_standards, emerging_market_biotech_firms).
narrative_ontology:constraint_victim(cellular_manipulation_standards, independent_researchers).
narrative_ontology:constraint_victim(cellular_manipulation_standards, global_equity_in_access).

/* ==========================================================================
   3. INDEXED CLASSIFICATIONS (P, T, E, S)
   ========================================================================== */

% PERSPECTIVE 1: INDEPENDENT RESEARCHER IN GLOBAL SOUTH (SNARE) — Faces near-insurmountable barriers: equipment costs ($500K–$2M for CRISPR labs), regulatory compliance ($50K–$200K annually), institutional affiliation requirements, and access to regulated materials. Cannot exit without abandoning research trajectory. Maximum experienced extraction from standardization regime that was designed without their participation.
constraint_indexing:constraint_classification(cellular_manipulation_standards, snare,
    context(agent_power(powerless),
            time_horizon(biographical),
            exit_options(trapped),
            spatial_scope(global))).

% PERSPECTIVE 2: EMERGING MARKET BIOTECH FIRM (TANGLED ROPE) — Constrained by compliance costs and material access restrictions but genuinely benefits from standardized protocols (reducing R&D time, enabling international collaboration, accessing quality-controlled reagents). Significant extraction but meaningful coordination benefit exists. Exit is possible at substantial cost (relocation, pivot to different technology platform).
constraint_indexing:constraint_classification(cellular_manipulation_standards, tangled_rope,
    context(agent_power(moderate),
            time_horizon(biographical),
            exit_options(constrained),
            spatial_scope(national))).

% PERSPECTIVE 3: ESTABLISHED BIOTECH CORPORATION (ROPE) — Primary beneficiary. Standards enable scale (certified reagents, interoperable protocols, regulatory predictability). High capital and compliance costs are easily absorbed. Exit costs are low due to institutional resources and diversification. Experiences the constraint as pure coordination — standardization reduces uncertainty and enables value capture through first-mover advantage in regulated markets.
constraint_indexing:constraint_classification(cellular_manipulation_standards, rope,
    context(agent_power(institutional),
            time_horizon(immediate),
            exit_options(arbitrage),
            spatial_scope(global))).

% PERSPECTIVE 4: NATIONAL REGULATORY AUTHORITY (TANGLED ROPE) — Constrained by: (a) capacity to evaluate novel technologies (expertise bottleneck), (b) alignment with international standards vs. national sovereignty, (c) pressure to enable innovation vs. public safety mandate. Enforces the constraint (actively maintains standards compliance) while itself partly captured — standards are often written by corporate/developed-world actors, and adoption is presented as necessary for participation in global biotech ecosystem.
constraint_indexing:constraint_classification(cellular_manipulation_standards, tangled_rope,
    context(agent_power(institutional),
            time_horizon(biographical),
            exit_options(constrained),
            spatial_scope(global))).

% PERSPECTIVE 5: OPEN SCIENCE & GLOBAL HEALTH COALITION (SCAFFOLD) — Organized agents (WHO, open-source biotech initiatives, patent pool advocates) see standards as a temporary barrier to be replaced by parallel infrastructure: open-source CRISPR tools (CRISPR-X, Inscripta open platforms), equitable reagent access programs, and regional capacity-building. Mobile exit options through technology transfer and community-led standards-setting. Sunset: 10–15 years for open alternatives to mature.
constraint_indexing:constraint_classification(cellular_manipulation_standards, scaffold,
    context(agent_power(organized),
            time_horizon(generational),
            exit_options(mobile),
            spatial_scope(global))).

% PERSPECTIVE 6: INSTITUTIONAL BIOSAFETY COMMITTEE SYSTEM (PITON) — Originally designed for containment assessment of recombinant organisms, now largely performing theater for CRISPR germline edit oversight. Committees often lack expertise in gene editing specificity; review processes are checklist-based rather than mechanistic. The system persists through institutional inertia despite degraded function — it has become a performative gate rather than a genuine safety evaluation mechanism. Theater ratio high because the actual biological risk assessment happens upstream (designer verification) or downstream (clinical trials), not in committee deliberation.
constraint_indexing:constraint_classification(cellular_manipulation_standards, piton,
    context(agent_power(institutional),
            time_horizon(civilizational),
            exit_options(arbitrage),
            spatial_scope(global))).

% PERSPECTIVE 7: ANALYTICAL OBSERVER / BIOSAFETY NATURAL LAW VIEW (MOUNTAIN) — From a civilizational perspective, some standardization of cellular manipulation is inherent to managing dual-use risk: powerful biotechnologies have irreversible outcomes, require institutional oversight, and demand international coordination. This perspective risks naturalizing a contingent governance arrangement as an immutable law of biology. The classification appears as a false summit — the engine will flag the contradiction between the natural law framing and the structural evidence of institutional extraction.
constraint_indexing:constraint_classification(cellular_manipulation_standards, mountain,
    context(agent_power(analytical),
            time_horizon(civilizational),
            exit_options(analytical),
            spatial_scope(universal))).

/* ==========================================================================
   4. VALIDATION TESTS
   ========================================================================== */

:- begin_tests(cellular_manipulation_standards_tests).

test(perspectival_gap) :-
    constraint_indexing:constraint_classification(cellular_manipulation_standards, TypePowerless, context(agent_power(powerless), _, _, _)),
    constraint_indexing:constraint_classification(cellular_manipulation_standards, TypeOther, context(agent_power(moderate), _, _, _)),
    TypePowerless \= TypeOther.

test(extraction_signature) :-
    domain_priors:base_extractiveness(cellular_manipulation_standards, E),
    E >= 0.46. % Ensures high-extraction Snare/Tangled territory.

test(piton_threshold) :-
    domain_priors:theater_ratio(cellular_manipulation_standards, TR),
    TR >= 0.70.

:- end_tests(cellular_manipulation_standards_tests).

/* ==========================================================================
   5. GENERATIVE COMMENTARY
   ========================================================================== */

/**
 * LOGIC RATIONALE:
 *   Extractiveness (0.52): Moderate-high, rising trend. Initial value (0.28) reflects primarily coordination: standardized protocols genuinely reduce R&D time, enable reagent quality assurance, facilitate knowledge exchange. Current value (0.52) reflects layered extraction as technology became economically valuable — equipment manufacturers, proprietary tool companies, and regulatory consulting firms capture rents through compliance complexity and material gatekeeping. The rising trajectory indicates rent-seeking accumulation, not improved coordination. Suppression (0.65): High. Barriers include equipment costs ($500K–$2M for full CRISPR lab), institutional affiliation requirements (many regulations require university or medical center sponsorship), regulatory compliance complexity ($50K–$200K annually), and restricted reagent access (some proprietary CRISPR variants require licensing). These are not equally distributed — they fall hardest on independent researchers and early-stage firms in resource-limited settings. Theater ratio (0.58): Moderate-high, rising. Institutional Biosafety Committees originally designed for contained release assessment of recombinant organisms; CRISPR germline edits are outside their original scope. Committee review is largely checklist-based (off-target risk mitigation, regulatory alignment, scientific merit) rather than mechanistic assessment. Actual risk control happens upstream (in designer/sequence analysis) and downstream (in clinical trials), not in committee deliberation. The rising trajectory reflects increasing gap between the review ritual and actual risk management as CRISPR technology advances.
 *
 * PERSPECTIVAL GAP:
 *   This constraint demonstrates stark perspectival divergence. The established biotech corporation sees pure coordination (Rope) — standardization solves their real problem of technology integration and market uncertainty. The open science coalition sees a temporary barrier being dismantled (Scaffold) — parallel open-source platforms, patent pools, and decentralized capacity-building are building exit paths. The regulatory authority sees mixed coordination and capture (Tangled Rope) — they enforce standards while recognizing they are partly writing rules others wrote for them. The emerging market firm sees both benefit and burden (Tangled Rope) — genuine coordination value but significant extraction. The independent researcher sees extraction with no escape (Snare) — barriers are absolute, costs are total, benefits are minimal. The biosafety committee system sees its own degradation (Piton) — formerly functional institutional mechanism now performing theater. The analytical observer risks seeing immutable biosafety necessity (Mountain) — but the structural data reveals this as a false summit naturalizing contingent governance choices.
 *
 * DIRECTIONALITY LOGIC:
 *   Directionality (d) is determined by structural position: whether the agent benefits from or bears costs from the constraint. Established biotech corporations are beneficiaries (low d, ~0.10–0.20): they have resources to meet compliance costs, gain market advantage from standardization, and can arbitrage the regulatory environment. Independent researchers in Global South are victims (high d, ~0.90–0.95): they bear compliance costs without ability to pass them on, lack resources to absorb barriers, and cannot arbitrage around restrictions. Emerging market firms are mixed (moderate d, ~0.55–0.65): they benefit from standardized protocols but bear disproportionate compliance costs. Regulatory authorities are constrained institutional actors (moderate d, ~0.60): they enforce the constraint while being partly captured by international standards and corporate influence in standards-setting bodies. Open science coalition has high exit optionality (moderate d, ~0.45–0.55): they can pursue parallel infrastructure without bearing full compliance costs of the mainstream system. The powerless/trapped perspective derives maximum d (~0.95); the beneficiary/arbitrage perspective derives minimum d (~0.10); the analytical perspective derives canonical d (~0.73).
 *
 * MANDATROPHY ANALYSIS:
 *   The mandatrophy is resolved by recognizing that cellular manipulation standards perform genuine coordination (technical interoperability, quality assurance, knowledge exchange) while simultaneously enabling rent-seeking extraction through barrier concentration and asymmetric compliance burden distribution. The constraint is legitimately Tangled Rope: both coordination and extraction are real and structurally necessary. The classification error would be either pure Rope (ignoring the extraction) or pure Snare (ignoring the coordination). The perspectival diversity confirms the mixed type — beneficiaries experience rope, victims experience snare, regulatory actors experience capture (modified tangled rope), organized alternatives experience scaffold. The theater ratio progression indicates that institutional mechanisms (biosafety committees) are becoming increasingly performative, which is consistent with piton dynamics but does not override the tangled rope base classification — the piton is a subordinate institutional mechanism within the broader tangled rope coordination-extraction hybrid.
 */

/* ==========================================================================
   6. OMEGA VARIABLES (Ω) - IRREDUCIBLE UNCERTAINTIES
   ========================================================================== */

omega_variable(
    dual_use_containment_threshold,
    'What level of biosafety certification and monitoring is genuinely required for CRISPR safety versus what is institutional theater masquerading as safety?',
    'Comparative analysis of germline edit safety outcomes across regulatory regimes (high-oversight vs light-touch); correlation between oversight intensity and actual adverse outcomes',
    'If genuinely required: standards reflect real risk and suppression values are underestimated. If theater dominates: standards are primarily rent-seeking (extraction higher than measured).',
    confidence_without_resolution(high)
).

narrative_ontology:omega_variable(dual_use_containment_threshold, empirical, 'Dual-use containment threshold: genuine safety vs institutional theater').

omega_variable(
    open_source_technical_sufficiency,
    'Can decentralized, open-source CRISPR platforms (CRISPR-X, open reagent libraries) deliver equivalent outcomes to proprietary platforms without centralized quality control?',
    'Head-to-head empirical comparison of off-target mutation rates, editing efficiency, reproducibility across open vs proprietary tools; assessment of quality control failure modes',
    'If technically sufficient: scaffold sunset is real, and decentralized alternatives can displace centralized standards. If insufficient: open-source gap reveals genuine coordination function in current standards.',
    confidence_without_resolution(medium)
).

narrative_ontology:omega_variable(open_source_technical_sufficiency, empirical, 'Technical sufficiency of open-source CRISPR platforms').

omega_variable(
    global_south_participation_gap,
    'How much of the suppression (barriers to entry in Global South) is due to unavoidable infrastructure costs versus imposed regulatory complexity designed to concentrate market control?',
    'Cost-benefit analysis comparing: (a) minimal viable CRISPR lab setup with basic quality assurance, (b) current regulatory compliance requirements; interviews with early-stage biotech in India, Brazil, Kenya; tracking of parallel informal gene-editing networks',
    'If infrastructure costs dominate: suppression is structural (equipment scarcity) and cannot be lowered without capital. If regulatory complexity dominates: suppression is extractive (can be reduced without sacrificing safety).',
    confidence_without_resolution(medium)
).

narrative_ontology:omega_variable(global_south_participation_gap, empirical, 'Global South participation gap: infrastructure vs regulatory barriers').

omega_variable(
    capacity_building_efficacy,
    'Do existing capacity-building and technology transfer programs (Gates Foundation biotech initiatives, Wellcome Trust partnerships) actually decentralize standards capability or do they create dependent relationships that reinforce centralized control?',
    'Longitudinal tracking of partner institutions post-capacity-building: rate of independent standard-setting, proportion of funding from local vs external sources, emergence of indigenous regulatory frameworks',
    'If genuinely decentralizing: scaffold dynamics confirmed, sunset plausible. If creating dependency: programs are extractive masquerade, and suppression is structural rather than being reduced.',
    confidence_without_resolution(medium)
).

narrative_ontology:omega_variable(capacity_building_efficacy, empirical, 'Capacity-building program efficacy and dependency dynamics').


/* ==========================================================================
   7. INTEGRATION HOOKS
   ========================================================================== */

narrative_ontology:interval(cellular_manipulation_standards, 0, 10).

/* ==========================================================================
   8. TEMPORAL MEASUREMENTS (LIFECYCLE DRIFT DATA)
   ========================================================================== */

% Theater ratio over time
narrative_ontology:measurement(cellman_tr_t0, cellular_manipulation_standards, theater_ratio, 0, 0.35).
narrative_ontology:measurement(cellman_tr_t5, cellular_manipulation_standards, theater_ratio, 5, 0.48).
narrative_ontology:measurement(cellman_tr_t10, cellular_manipulation_standards, theater_ratio, 10, 0.58).

% Extraction over time
narrative_ontology:measurement(cellman_be_t0, cellular_manipulation_standards, base_extractiveness, 0, 0.28).
narrative_ontology:measurement(cellman_be_t5, cellular_manipulation_standards, base_extractiveness, 5, 0.4).
narrative_ontology:measurement(cellman_be_t10, cellular_manipulation_standards, base_extractiveness, 10, 0.52).


/* ==========================================================================
   9. BOLTZMANN & NETWORK DATA
   ========================================================================== */

narrative_ontology:coordination_type(cellular_manipulation_standards, resource_allocation).
narrative_ontology:boltzmann_floor_override(cellular_manipulation_standards, 0.18).
narrative_ontology:affects_constraint(cellular_manipulation_standards, gene_therapy_access_equity).
narrative_ontology:affects_constraint(cellular_manipulation_standards, dual_use_biotech_governance).
narrative_ontology:affects_constraint(cellular_manipulation_standards, intellectual_property_biotechnology).

% DUAL FORMULATION NOTE:
% Cellular manipulation standards decompose into three related constraints: (1) technical standardization for safety/interoperability (this story, ε=0.52), (2) global access equity (separate story, ε=0.68, Snare), (3) dual-use biosecurity governance (separate story, ε=0.55, Tangled Rope). Each has distinct ε values because they address different aspects of the standards regime. Technical coordination standards have moderate extraction; access barriers have high extraction; biosecurity governance has embedded capture dynamics. The three stories are linked: technical standards affect access outcomes affect dual-use risk assessment.

/* ==========================================================================
   10. DIRECTIONALITY OVERRIDES (v6.0, OPTIONAL)
   ========================================================================== */

constraint_indexing:directionality_override(cellular_manipulation_standards, institutional, 0.42).

/* ==========================================================================
   END OF CONSTRAINT STORY
   ========================================================================== */
